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Abstract
Background: HIV incidence among South African adolescent girls and young women (AGYW) remains high, but
could be reduced by highly effective pre-exposure prophylaxis (PrEP). Unfortunately, AGYW report significant
barriers to clinic-based sexual and reproductive health services. Even when AGYW access PrEP as an HIV prevention
method, poor prevention-effective use was a serious barrier to achieving its optimal HIV prevention benefits.
Determining the acceptability and feasibility of community-based platforms to increase AGYW’s access to PrEP, and
evaluating behavioural interventions to improve prevention-effective use of PrEP are needed.
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Methods: We propose a mixed-methods study among AGYW aged 16–25 years in Eastern Cape Province, South
Africa. In the first component, a cross-sectional study will assess the acceptability and feasibility of leveraging
community-based HIV counselling and testing (CBCT) platforms to refer HIV-negative, at-risk AGYW to non-clinic-
based, same-day PrEP initiation services. In the second component, we will enrol 480 AGYW initiating PrEP via our
CBCT platforms into a three-armed (1:1:1) randomized control trial (RCT) that will evaluate the effectiveness of
adherence support interventions to improve the prevention-effective use of PrEP. Adherence will be measured over
24 months via tenofovir-diphosphate blood concentration levels. Qualitative investigations will explore participant,
staff, and community experiences associated with community-based PrEP services, adherence support activities,
study implementation, and community awareness. Costs and scalability of service platforms and interventions will
be evaluated.
Discussion: This will be the first study to assess the acceptability and feasibility of leveraging CBCT platforms to
identify and refer at-risk AGYW to community-based, same-day PrEP initiation services. It will also provide
quantitative and qualitative results to inform adherence support activities and services that promote the
prevention-effective use of PrEP among AGYW. By applying principles of implementation science, behavioural
science, and health economics research, we aim to inform strategies to improve access to and prevention-effective
use of PrEP by AGYW.
Trial registration: ClinicalTrials.gov NCT03977181. Registered on 6 June 2019—retrospectively registered.
Keywords: HIV, HIV prevention, PrEP, Randomized controlled trial, Adolescent girls and young women, Community-
based delivery platforms, Adherence support intervention, Cost-effectiveness, South Africa
Background
In 2017, 1.8 million people were infected with human
immunodeficiency virus (HIV), most of whom live in
Southern and Eastern Africa [1]. There exist significant
differences in HIV incidence and prevalence by age and
sex, with young women being particularly vulnerable to
HIV [2–7]. In South Africa, specifically, HIV incidence
and prevalence among adolescent girls and young
women (AGYW) ages 15–24 is significantly higher than
their male counterparts (incidence = 1.51% per year vs.
0.49% per year, respectively; prevalence = 10.9% vs 4.8%,
respectively) [8]. Significant risk factors include having
concurrent or older sexual partners [9–11] as well as
interpersonal violence [12, 13]. Consequently, there is an
urgent need for effective HIV prevention strategies tar-
geted at young women and under their control, to re-
duce HIV incidence among this key population.
Pre-exposure prophylaxis (PrEP) with emtricitabine
(FTC)/tenofovir (TDF) as a method of HIV prevention has
demonstrated significant efficacy in clinical trials among
different population groups, with efficacy being strongly as-
sociated with increased drug adherence [14–18]. Previous
and current PrEP demonstration projects have largely fo-
cused on providing PrEP through clinic-based delivery plat-
forms, including antiretroviral therapy (ART), sexually
transmitted infections (STI), family planning, and
adolescent-friendly clinics [19–21]. While clinic-based ser-
vices may provide good opportunity for service integration,
leveraging these facility-based services for PrEP provision
may be fraught with barriers including perceived lack of
confidentiality and privacy at health centres [22–24],
unfriendly clinic staff [25, 26], long queues, inconvenient
operating hours, and a perceived predominant focus on
maternal-child health with no AGYW-focused services [27,
28].
Interventions associated with adolescent health should
be adolescent-centred, with services leveraging
community-based delivery platforms and not rigid, med-
icalized, clinic-based venues [29]. Recent findings from
an at-scale community-based HIV counselling and test-
ing (CBCT) programme implemented in South Africa
found that AGYW had the highest testing uptake across
all age groups of either sex, regardless of district type
(i.e. urban, rural, peri-urban) [30]. Given that HIV test-
ing is the entry point for PrEP service delivery, lever-
aging CBCT platforms to effectively identify and link
young women to PrEP services should be considered as
a supply-side intervention for scaling up PrEP.
Community-based programmes aimed at support-
ing ART adherence and retention in care have been
recognized as effective and sustainable approaches to
achieving the UNAIDS 90-90-90 targets [31–37].
One of the most innovative and successful adherence
support interventions has been “adherence clubs”.
Adherence clubs are a cost-effective intervention
strategy that can be locally adapted to low-resource
settings and implemented by non-specialists and lay
health workers with little formal counselling experi-
ence [37–40]. As PrEP becomes more widely avail-
able, rigorously evaluated adherence skill-building
interventions, implemented through community-
based platforms, will provide invaluable information
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regarding the optimal structure, content, and deliv-
ery of PrEP adherence support programmes.
Study rationale and aims
Few studies have explored effective strategies to identify
and deliver non-clinic-based PrEP services to at-risk
populations, how to support prevention-effective use
and retention in PrEP care, or implementation science
approaches to scaling up PrEP delivery. Given that
CBCT platforms have been shown to be highly accept-
able and accessible to adolescent girls and young
women, it is crucial to understand if these platforms can
also be used to identify and deliver PrEP to at-risk youth
[14–16]. Furthermore, community-based prevention-
effective PrEP adherence support is critical to reduce the
HIV burden among AGYW in South Africa. Towards
this, our study aims include (Table 1):
Aim 1: PrEP service delivery: To determine the
acceptability and feasibility of PrEP uptake by AGYW
when delivered through community-based HIV coun-
selling and testing platforms;
Aim 2: PrEP adherence support: To evaluate
community-based, scalable interventions to achieve
prevention-effective adherence to PrEP among AGYW;
and
Aim 3: Scalability of community-based PrEP services: esti-
mate the cost per AGYW initiated on PrEP and provided
adherence support through community-based platforms,
and the cost per incident HIV infection averted.
Methods
Study design and flow
The Community PrEP Study will enrol a cohort of 480
HIV-negative South African AGYW aged 16–25 years,
Table 1 Study overview: aims, rational, hypothesis, design and outcomes
Hypothesis Rational Study design and
approach




facilitate access to and
initiation of PrEP by
adolescent girls and young
women
Numerous barriers exist
that delay or inhibit YW’s






services into CBCT pop-up
testing sites and home-
based testing platforms in
extremely high HIV burden
and under-researched rural
and urban settings of
South Africa
The proportion of eligible
young women accepting
PrEP as part of CBCT
services
(1) PrEP initiation rates by
a) community type (urban
vs. rural), and b) CBCT
platform (pop-up testing
sites vs systematic home-
based testing);
(2) In-depth qualitative un-
derstanding of immediate,










programmes will be asso-
ciated with a substantial
increase in prevention-
effective use of PrEP com-
pared to a control
Lack of PrEP efficacy in
African YW in clinical trials
was strongly associated
with poor adherence. To
maximize the prevention





Enrol and randomize PrEP-
accepting young women to







levels in dried blood spots




(1) Predictors of PrEP
adherence after adjusting
for study arm, socio-
demographic factors, ex-
posure to adherence sup-












and factors associated with






increase uptake of and
adherence to PrEP among
YW, and cost-effectively
avert HIV infections com-
pared to standard practice
Evidence on cost and
cost-effectiveness can be
used by decision makers
regarding the use of re-







tiation and adherence sup-
port programmes among








will evaluate costs incurred
and costs averted;
(2) Estimate impact of
support interventions on
HIV incidence, HIV-related
deaths and DALYs, using
proportion on PrEP
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incorporating multiple study designs to address our
three main study aims (Table 1). Specifically, a cross-
sectional, mixed-methods study design will be used to
quantitatively measure and qualitatively assess the ac-
ceptability and feasibility of using CBCT platforms to
identify HIV-uninfected AGYW and offer PrEP (Aim 1).
A randomized controlled trial will evaluate a behavioural
intervention aimed at supporting prevention-effective
adherence to PrEP (Aim 2). Finally, we will perform
micro-costing and mathematical modelling analyses to
calculate the cost-effectiveness of our PrEP delivery plat-
form and adherence support programmes (Aim 3). Com-
munity advisory boards (CABs) were established to
facilitate community engagement and acceptance, elicit
feedback on study design, conduct analysis, and ensure
that community views and perspectives were appropri-
ately incorporated in a collaborative manner.
Study location
This study is being conducted in Buffalo City Metro
(BCM) Health District, Eastern Cape Province, South Af-
rica (Fig. 1). In 2016, BCM had an estimated mid-year
population of 834,998 people. In 2016, the South African
National Department of Health estimated that BCM had a
general population HIV prevalence of 12.4% and incidence
of 0.54%; an adult (15+ years old) HIV prevalence of
17.1% and incidence of 0.74%; and a female youth (age
15–24 years) HIV prevalence of 12.8% and incidence of
2.40% [41]. Within BCM, our study will be conducted in
one urban and one rural community. Selection of study
communities was conducted in consultation with the
BCM Department of health and was informed by census
data, absence of other ongoing HIV prevention studies,
and community willingness to be involved in the study.
Intervention design and adherence support activities
Description of the intervention
The intervention arms were developed using the
Information-Motivation-Behavioural Skills Model of Be-
haviour Change (IMB) [42, 43]; the IMB model has been
used extensively to improve medication adherence, in-
cluding for ART [42–44] and daily contraceptives [45].
Intervention arms will incorporate content from the
evidence-based intervention Life Steps [46], as well as
from the HIV Prevention Trials Network 082 study [47]
and the 3Ps for Prevention open-label PrEP demonstra-
tion study [48]. Using standardized manuals, adherence
support interventions will be delivered in either a group
(Arm 1) or one-on-one individual (Arm 2) sessions. Par-
ticipants randomized to intervention arms will be seen
by adherence counsellors monthly for 24 months at a
fixed community-based site.
Control
Control participants will receive passive adherence sup-
port consistent with standard of care for PrEP
Fig. 1 Provincial map of South Africa showing location of study communities within Buffalo City Metro Health District, Eastern Cape Province
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programmes delivered by public sector health clinics.
Control participants will return monthly to collect medi-
cation refills, report and receive support for side effects,
and conduct special study activities (i.e. specimen collec-
tion; Table 2).
Monthly activities will include (1) attendance check-in,
(2) adherence support session (intervention arms only),
(3) clinical assessment, (4) medication dispensing, (5)
study visit reminders, and (6) study pack and voucher.
Each month, study staff will contact participants up to
three times via SMS and phone calls as study visit re-
minders to support retention. More details about inter-
vention and control arms is available in Table 3.
Randomization
Randomization will occur following participant consent
and confirmatory pregnancy testing. Independent ran-
dom allocation lists will be created by the study Data
Manager for each study site (urban vs. rural), with study
staff and participants blinded to the allocation scheme.
Participants will be randomized to study arms in a 1:1:1
ratio using computer-generated quasi-random numbers
and permuted blocks of 18, within the randomization
module of Research Electronic Data Capture (REDCap)
[49]. Since the randomization occurs at the community-
based study sites, it is impossible to blind study team
members or participants to the randomization assign-
ments. However, procedures to minimize the influence
of the unblinded nature of this study on outcomes have
been implemented. Ongoing data monitoring does not
include information about study endpoints disaggregated
by study site or study arm. Although the study biostatis-
tician reviews data on PrEP uptake and adherence by
study arm and site, the final outcome is always blinded.
Recruitment
Participants will be recruited from community-based
HIV counselling and testing platforms established in
study communities for the purpose of this study. Con-
sent and enrolment will be conducted by field-based en-
rolment counsellors.
HIV testing and testing platforms
Two different CBCT modalities, pop-up site and home-
based testing, will be leveraged in each community. HIV
testing will be conducted in accordance with South Afri-
can national guidelines [50]. Referrals to local HIV treat-
ment services will be provided to those with a confirmed
positive result.
Pop-up testing sites Three pop-up testing sites will be
leveraged in each study community. The main site (Site
A) will be a fixed-positioned testing venue co-located
with a centralized community venue for the full duration
of the study. A second site (Site B) will be a semi-mobile
container co-located with another recognizable commu-
nity venue during enrolment. A third site (Site C) will be
a highly mobile testing tent placed at peripheral loca-
tions in each community, and repositioned 2–3 times
during enrolment.
Door-to-door home-based testing Prior to initiating
home-based testing activities, GIS maps will be obtained
for each community, with 24 urban and 26 rural small-
block areas delineated and individual houses plotted for
targeted testing. Detailed maps and electronic tablets
will be used to track the small-block areas and houses
visited and tested. Home-based testing will be performed
until all houses are visited at least once.
PrEP initiation and study enrolment
Baseline screening for referral for PrEP study and
services Prior to screening, participants will be asked to
provide fingerprints to facilitate participant identification
during subsequent study activities; fingerprints will be
Table 2 Study related events and time points
Baseline M1 M2 M3 M6 M9 M12 M15 M18 M21 M24
Routine study activities
HIV and pregnancy testing X X X X X X X X X
Group and individual adherence support X X X X X X X X X X
PrEP medication pickup X X X X X X X X X X
Special study activities*
ACASI Questionnaire X X X X
CrCl testing X X X X
STI testing X X X X
Blood testing for detectable TFV-DP X X X X X
Hepatitis B testing and vaccination X X X
* A R30.00 (~$2.00) voucher will be provided after each “special” study visit where specimens are collected (i.e. M3, 6, 12, 18, and 24)
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collected using the FS88 Futronic Fingerprint Scanner
[Futronic Technology Company, Kwai Fong, Hong
Kong]. Participants will then be asked to complete an
audio computer-assisted self-interviewing (ACASI) ques-
tionnaire collecting socio-demographic, behavioural, and
clinical histories; HIV knowledge, attitudes, and practice;
and a self-reported HIV risk survey. Upon completing
the ACASI, participants will watch a PrEP informational
video [51], followed by an interviewer-administered
screening tool to assess whether the participant is cur-
rently (1) interested in learning more about PrEP, (2) in-
terested in taking PrEP, (3) using post-exposure
prophylaxis (PEP), (4) participating in other HIV preven-
tion studies, (5) pregnant, (6) breast feeding, (7) on TB
treatment, or (8) has signs or symptoms of acute HIV in-
fection. Responses will be captured in real time using
REDCap.
Inclusion/exclusion criteria A candidate is eligible for
referral to PrEP initiation services if they (1) are aged
16–25 years; (2) self-identify as female; (3) have a HIV-
negative test result obtained from a study-associated
CBCT site; (4) plan on residing in the study community
for at least 12 months; (5) complete the baseline ques-
tionnaire; (6) express interest in taking PrEP; (7) not tak-
ing TB treatment; (8) not pregnant or breastfeeding; (9)
not currently using PEP; (10) not currently participating
in other HIV prevention studies; (11) do not have signs
or symptoms of acute HIV infection; (12) understand
English or IsiXhosa. Of note, given the likelihood of so-
cial desirability bias, structural risk factors, and the dy-
namic nature of HIV risk among South African AGYW,
prior sexual activity will not be used as inclusion/exclu-
sion criterion [8, 52, 53].
Referral for PrEP services and study enrolment Eli-
gible participants interested in PrEP will be provided a
copy of their HIV test results and a referral letter for
PrEP initiation at our study sites, which will be co-
located with pop-up testing sites A and B. Upon present-
ing to a PrEP study site, participants will be consented,
asked to provide contact details, tested for syphilis and
pregnancy, and asked to submit a self-collected vaginal
swab for further STI testing (Table 2). If pregnant, par-
ticipants will be provided a referral letter for antenatal
care services in lieu of PrEP initiation, as South Africa
has not yet approved PrEP initiation during pregnancy.
Prior to departure, participants will receive their syphilis
test results, with a treatment referral if applicable.
Participants will be asked to provide a blood sample
for hepatitis B testing and creatinine clearance, random-
ized, and then provided a 30-day supply (1 bottle) of
DIDIVIR (CIPLA generic for Emtricitabine 200mg/
Tenofovir Disoproxil Fumarate 300 mg); those random-
ized to an intervention group will be reminded of their
first adherence session date. All participants will be
asked to return for an orientation visit 2 weeks post-
enrolment to meet with their adherence counsellor, and
a study nurse to review any test results, assess side ef-
fects and acute HIV symptoms, and receive the first of
three hepatitis B injections if indicated.
Data collection, management, and oversight
A mixed-methods approach will be used to collect data
from participants and study staff throughout the 2-year
study follow-up period.
Quantitative data
Quantitative data will be captured at baseline and again
at months 3, 12, and 24 via ACASI, about participants’
sexual behaviour, risk factors, self-perception of HIV ac-
quisition risk, partner characteristics and HIV status,
knowledge and attitudes towards PrEP, perceived bar-
riers and facilitators of PrEP uptake and adherence, pro-
jected HIV stigma, alcohol and drug use, mental health,
and social support [54–57]. Basic adherence tracking,
specimen collection, test results, and participant time-
lines will be monitored on REDCap.
Table 3 Components of adherence interventions
*Study packs included sanitary pads, condoms, snack, and medication refill reminder card
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Qualitative data
Qualitative data (Table 4) will be collected using in-
depth interviews (IDIs) and community mapping exer-
cises (CMEs) with AGYW, focus group discussions
(FGDs) with community advisory board members, and
staff exchange programmes. All IDI and FGD guides will
be semi-structured, and studies will be conducted in the
preferred language of the participant.
AGYW interviews
AGYW interviews will be used to understand their deci-
sions on whether or not to access PrEP services, timing
of PrEP initiation, early product experience, and disclos-
ure challenges. A second cadre of interviews will focus
on motivation of continued PrEP use and factors influ-
encing adherence. During these interviews, participants
will complete two mapping activities: (1) community
map of their neighbourhoods to outline social settings
influencing PrEP uptake and adherence; and (2) map of
their home to describe resources (water/ food security,
privacy etc.) and family factors influencing PrEP man-
agement and dosing plans. A third group of interviews
will explore special circumstances occurring among
study participants.
Community advisory board (CAB) and staff exchange
programmes (SEPs)
We will conduct FGDs to assess CAB experiences and
perspectives of community acceptability of PrEP for
AGYW. A SEP using observations and staff IDIs will
allow those doing the same work at different sites to
recognize and discuss implementation differences that
may inform optimized service delivery and participant
engagement. FGDs and SEPs will assess community and
study impact on adherence or attendance, as well as de-
termining additional differences in community and
organization that may influence these study outcomes.
Data management and quality assurance
Data will be stored in a secure, password-protected,
web-based database which will only be accessible to au-
thorized project staff. Tablet computers used for ACASI
interviews will be password protected and will be stored
securely at the Foundation for Professional Development
(FPD) offices in the study districts. Paper records of par-
ticipants will be kept in lockable filing cabinets at FPD
offices. Paper records, excluding informed consent
forms, will only contain PINs. A separate, access-
controlled, link log database will be developed and main-
tained by the data manager. Qualitative data including
audio files and password-protected transcripts will be
stored on a secure, access-controlled cloud-based data-
base (SharePoint). Double-data entry of laboratory re-
sults will be employed when capturing participant data
onto RedCap. Automated data quality checks and skip
patterns will be built into RedCap and ACASI. Research
assistants will conduct onsite data quality checks daily.
Scheduled and unscheduled data quality inspections will
be carried out by the data quality assurance personnel in
order to ensure high data quality standards. The princi-
pal investigators, or their designate, will randomly select
10% of all participant files for inspection every 3 months.
Study oversite, data safety and monitoring board (DSMB),
and study auditing
The co-principal investigators/corresponding authors
take responsibility for the scientific validity of the study
protocol, assessment of study quality and conduct, as
well as for the scientific quality of the final study report.
The primary author oversees the coordinating centre
and takes responsibility for the day-to-day study imple-
mentation in collaboration with three other co-authors
(Foundation for Professional Development). A DSMB
will be made up of four invited national and inter-
national experts, at least two of whom are clinically
trained and knowledgeable about PrEP and at least one
biostatistician. DSMB members will have no direct asso-
ciation with this study and will be independent from any
professional or financial conflict of interest with the re-
search project and/or study investigators. The DSMB
will review in aggregate on a bi-annual basis, any adverse
events (AEs) that occur. Though no serious adverse
events (SAEs) are reasonably expected during this trial,
should they occur the DSMB will review them in real
time. Trial conduct will be continuously audited as part
of quarterly meetings of the study team, and annually by
the University of Cape Town Human Research Ethics
Committee as part of mandatory renewal of ethics
approval.
Laboratory testing, STI treatment, and clinical follow-up
HIV rapid testing
HIV counselling and testing will be performed every 3
months, per South African national guidelines [50]
(Table 2). Those with a positive confirmatory test will
have venous blood drawn to test for HIV drug resist-
ance. Furthermore, those testing positive for HIV will be
terminated from the study and provided a referral letter
for HIV care and treatment.
STI testing and treatment
We will test for Chlamydia trachomatis (CT), Neisseria
gonorrhoeae (NG), and Trichomonas vaginalis (TV)
using a self-collected vaginal swab at baseline and again
at months 6, 12, and 24. Self-collected swabs will be
shipped monthly to the National Institute for Commu-
nicable Diseases (NICD; Johannesburg, South Africa) for
nucleic acid amplification testing (NAAT) using the
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Table 4 Qualitative data collection schedule







Special circumstances among study participants











Two or more consecutive
missed visits





Reported social harms Participants who report any type of social harm due to study
participation.
i.e. participants treated unfairly and experiencing problems being
accepted by their families, partners, and/or communities due to







Participants who have a unique pattern of medication use as identified
by adherence counsellors or study nurses.








Participants who never presented to study sites for adherence




PrEP uptake from community platforms
Immediate acceptors Participants who consent to study and receive supply of PrEP the day





Immediate presenters Participants who present to study sites for PrEP initiation within 0-3





Early presenters Participants who present to study sites for PrEP initiation within 4-14





Late presenters Participants who present to study sites for PrEP initiation within 15-30











Experiences with taking PrEP and engaging in adherence support activities
High adherence Active participants who have attended more than one adherence









Low adherence Active participants who have attended more than one adherence









Process evaluation and staff implementation experiences
PrEP field staff Interviews with field staff, including research nurses, adherence
counsellors, and field workers to understand their experiences with
PrEP implementation at a community-based level.




Exchange of one staff member per site to observe differences in staff




Field Staff 1 day per site
Community preparation and engagement
CAB members Active community advisory members who advised study staff on study
implementation, study progress, and community engagement.
FGD CAB Members 4 FGDs
(2 per site)
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Aptima Combo 2® Assay (Hologic, San Diego, USA) for
Neisseria gonorrhoeae and Chlamydia trachomatis and
using the Aptima® Trichomonas vaginalis Assay (Holo-
gic, San Diego, USA) for Trichomonas vaginalis. Nega-
tive test results will be notified at the next study visit.
Positive test results will be notified immediately upon re-
sult availability via site-based visits or phone calls. Those
with a positive STI test result will be provided a copy of
their results and a treatment referral letter per South Af-
rican STI guidelines [58].
Syphilis testing will be conducted during the enrol-
ment visit only, using the Alere Determine™ Syphilis TP
rapid test. Negative tests will be reported by the study
nurse to participants; patients testing positive will be re-
ferred for further laboratory confirmatory testing and
treatment as indicated. All enrolled participants will be
tested for Hepatitis B antigen (HBsAg), performed by
the National Health Laboratory Service. Participants
with a negative test result will be provided hepatitis B
vaccination per the South African vaccination schedule
[59]; those that test positive will be asked to provide
blood for ALT and AST testing to determine liver func-
tion and referred for care and treatment. Neither the
syphilis nor hepatitis B test results will impact study
eligibility.
Pregnancy testing
Urine-based pregnancy testing to detect human chori-
onic gonadotropin will be conducted every 3 months. If
a participant becomes pregnant while enrolled in the
study, they will be provided referral letters for prenatal
support and care, and counselled on taking PrEP while
pregnant, and will be allowed to decide whether they
want to continue PrEP. Participants who continue taking
PrEP will be monitored by the study clinician and
nurses, with pregnancy milestone and birth outcomes
recorded and monitored.
Creatinine testing
Creatinine clearance will be assessed to monitor kidney
function at baseline, month 3, month 12, and month 24.
Clinical assessment for PrEP continuation will occur if
estimated glomerular filtration (eGRF) rate is less than
60mL/min. If eGRF does not improve, the participant
will be terminated from the study due to risk of kidney
damage and will be provided a referral letters for renal
management and care.
Tenofovir testing
To assess PrEP adherence, tenofovir-diphosphate levels
will be assessed at months 3, 6, 12, 18, and 24. Dried
blood spots (DBS) will be prepared from venous blood
and spotted on Whatman protein saver cards. Drug con-
centration testing will occur at the University of Cape
Town Division of Pharmacology laboratory using DBS
TDF testing protocols [60].
Sample size and power calculations
A sample size was calculated to have 80% power to de-
tect differences in the proportion of participants adher-
ing to PrEP among the three study arms (Aim 2) using
the chi-square test for independence with two degrees of
freedom, with an alpha of 0.05, and assuming an attri-
tion rate of 10% for those who (1) withdraw voluntarily
from the study, (2) initiate on PrEP but withdraw due to
adverse events (e.g. hepatic or renal abnormalities), or
(3) become ineligible for PrEP (e.g. seroconvert). The ef-
fect size estimate was informed by prior experience from
the field, where an effect size of 0.30 has been found be-
tween ART clients receiving some adherence support
and those receiving none. However, we use a more con-
servative effect size of 0.15, to account for the fact that
adherence support may not lead to the same gains in ad-
herence among HIV-negative PrEP clients as it does
with HIV-positive ART clients. The sample size was cal-
culated to be 160 per arm (480 total).
Primary and secondary outcomes
For Aim 1, our primary outcome will be the proportion
of eligible individuals accepting PrEP as part of CBCT
services. Secondary outcomes will include (1) stratifica-
tion of PrEP initiation by both location and CBCT plat-
form; (2) in-depth qualitative understanding of PrEP
initiation; (3) correlates of immediate, delayed, and no
PrEP initiation; and (4) comparison of sexual behaviours,
risk profiles, and self-perception of risk in immediate,
delayed, and never acceptors. Using the IMB model to
inform the selection of variables and contextualization of
results, an assessment of determinants of PrEP uptake
will include (1) socio-demographic factors, (2) risk be-
haviours, (3) self-perception of risk, (4) previous know-
ledge of PrEP and perception of those taking PrEP, (5)
partner characteristics and HIV status, (6) HIV-related
stigma, and (7) screening scores for depression, sub-
stance abuse, and social support. Baseline STIs will be
used as an independent marker of sexual risk behaviour,
and to validate self-reported sexual risk behaviours and
self-perception of risk.
For Aim 2, the primary outcome will be a comparison
of TFV-DP levels by study arm at months 3, 6, 12, 18,
and 24, with a 12-month primary outcome and 24-
month assessment of intervention durability. Based on
cumulative adherence behaviour, as measured in iPrEX
OLE [14], adherence will be categorized as (1) low ad-
herence (≤ 3 tablets per week; ≤ 699 fmol/DBS punch),
and (2) high adherence (4–7 tablets per week; ≥ 700
fmol/DBS punch). Analysis of primary outcomes will be
conducted on an intention-to-treat basis. Secondary
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outcomes will include (1) predictors of PrEP adherence
after adjusting for study arm, socio-demographic factors,
exposure to adherence support activities, and risk pro-
files; (2) characterization of changes in sexual behaviours
and risk profiles following PrEP initiation; (3) proportion
of individuals who discontinue PrEP and factors associ-
ated with discontinuation; (4) proportion of individuals
who discontinue but subsequently restart PrEP and
characteristics associated with this subgroup; (5) factors
associated with of patterns of PrEP use; and (6) profiles
of individuals that may benefit more from group-based
vs. individualized adherence support.
For Aim 3, we will estimate incremental costs relative
to standard practice for the intervention. Micro-costing
studies will use activity-based approaches for costs in-
curred (e.g. start-up activities, recruitment, service deliv-
ery, lab monitoring, adherence support, and PrEP) and
costs averted (e.g. health costs saved by averting HIV in-
fections). Adjusting for time spent on research activities
(e.g. informed consent, research questionnaires), the
total time required for the intervention will be estimated.
Time and costs for PrEP delivery through community-
based platforms will be estimated through staff inter-
views, accounting for time available for the intervention.
Costs incurred by patients to access PrEP will be
assessed through participant interviews. Furthermore,
we will estimate the impact of PrEP strategies by meas-
uring: (1) the difference in HIV incident cases among
intervention and control arm participants, (2) changes in
HIV incident cases at the population level, and (3)
changes in disability-adjusted life years (DALYs) be-
tween intervention and control arm participants. The
model simulates intervention impact and projects the ef-
fect on health outcomes over 10 years. Sensitivity ana-
lyses will explore the impact of PrEP uptake and
adherence on model outcomes outside a study setting,
reduction in HIV transmission due to ART adherence,
and PrEP supply-chain interruptions.
Data analysis
Descriptive statistics (e.g. means, standard deviations/
variances, medians with inter-quartile ranges, and fre-
quency distributions) will be used to describe participant
demographic characteristics. The chi-squared statistic
test will be used for categorical variables whereas T-test
(parametric) or Wilcoxon rank sum test (non-paramet-
ric) will be applied for continuous variables. Transforma-
tions of outcome variables will be explored and
performed if appropriate. Multivariate logistic regression
models will be performed to examine associations be-
tween covariates. Since data is collected on one subject
over time, the data will be treated as longitudinal data.
Generalized linear mixed effect models will be fitted to
determine associations of interest with time and
intervention effects included as fixed effects and allowing
for subject-specific random effects. Alternatively, gener-
alized estimating equations can be used to account for
any correlations of repeated data measures, when asses-
sing determinants of PrEP adherence at time points pro-
vided we have balanced data with ignorable missing
patterns. Time-to-event analysis will be conducted using
Kaplan-Meier plots. To determine possible associations
with covariates, a Cox-proportional hazard will be used.
If the proportional hazard assumption does not hold, an
accelerated failure time model will be used. Missing data
due to loss to follow-up is inadvertent and inevitable.
The extent of missing data will be assessed in the pri-
mary analysis. The primary analysis will be conducted
under the assumption of data Missing at Random
(MAR). As such, longitudinal likelihood-based data ana-
lysis, utilizing all the observed pre-deviation data from
each participant will be employed. Thereafter, multiple
imputation (MI) method will be employed under the pri-
mary MAR assumption, and Rubin’s rule will be
followed to combine results. Sensitivity to deviation from
the MAR assumption will be investigated. Intention to
treat (ITT) assessment with complete case approaches
where necessary will be implemented in cases of non-
adherence to randomization assignment. Depending on
the extent of non-adherence, the “as treated (AT)” ap-
proaches may be employed to analyse participants ac-
cording to the intervention received regardless to their
randomized allocation. A marker of level of adherence
can also be included in the models. Patterns of PrEP use
will be identified using latent class models or clustering
techniques and the association of factors with these la-
tent classes will be examined using multinomial logistic
regression modelling. For all statistical investigations,
tests for significance will be two-tailed. Analyses will be
conducted using STATA 13.0 or R version 4.
Qualitative data analyses of participant and staff IDIs,
CAB FGDs, CMEs, and staff SEPs will be conducted
using a constant comparison approach guided by the
study IMB framework. Data and results will be triangu-
lated using matrices to refine findings [61]. Transcripts
will be analysed by the qualitative research team, with
results presented to study leadership for review and to
guide additional analyses. Socio-behavioural factors and
contextual (urban v. rural) influences influencing young
women’s action plans for PrEP uptake and adherence
will be used to create risk and adherence profiles to in-
form eventual intervention tailoring and
implementation.
Ethical considerations and trial registration
PrEP has been approved for use by international and do-
mestic governing bodies in South Africa. Written in-
formed consent will be obtained from participants at
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multiple time points, including prior to baseline ques-
tionnaire, PrEP initiation, and any qualitative interviews.
The study protocol has received full ethical approval
from the University of Cape Town Human Research
Ethics Committee (Ref: 289/2018) and has been regis-
tered with ClinicalTrials.gov (NCT03977181). Any and
all protocol modifications and annual ethics renewal will
be submitted to the University of Cape Town Human
Research Ethics Committee for approval.
There are no anticipated problems that are detrimental
to the participants; however, expected clinical side ef-
fects of DIDIVIR include nausea, dizziness, and diar-
rhoea; study nurses will be trained on the Southern
African HIV Clinicians Guidelines for PrEP used to
identify and manage side effects [62]. All research staff
will be trained to identify, probe for, and report AEs and
social harms (SHs). Occurrence of AEs and SHs will be
collected at every visit and recorded in REDCap. All AEs
and SHs, with detailed study notes, will be internally
reviewed by the study team. An AE list will be compiled
and reviewed by the study DSMB and reported to Uni-
versity of Cape Town IRB. A study clinician will review
all abnormal test results, liaise with local clinic doctors,
and has the authority to terminate participants based on
clinical opinion. Upon completion of their 2-year follow-
up, all participants will be provided a referral to their
local clinics for continuation of PrEP services.
Dissemination plans
As results are available and finalized, they will be ana-
lysed for publication in peer-reviewed scientific journals
and presentation at relevant scientific conferences;
standard authorship guidelines will be followed, and no
professional writers will be used. Results will also be pre-
sented, orally and in writing, to local (i.e. Buffalo City
Metro District Department of Health), provincial (i.e.
Eastern Cape Provincial Department of Health, Eastern
Cape Provincial AIDS Council), and key national (i.e.
South African National Department of Health, South Af-
rican National HIV Think Tank) stakeholders. Results
will be reported back to study CABs, communities and
participants, via town hall style meetings and as 1-pager
flyers using infographics. Key interim results (i.e. # HIV
seroconversions, STI incidence, and pregnancies), imple-
mentation experiences, and lessons learned will be
shared with district and provincial stakeholders on a bi-
annual basis.
Discussion
The Community PrEP Study is an innovative, mixed-
methods study that aims to provide robust insights into
(1) the acceptability, feasibility, and uptake of PrEP as a
methods for HIV prevention by AGYW when delivered
through CBCT platforms, (2) community-based
prevention-effective adherence support for AGYW, and
(3) the cost-effectiveness of such community-based ap-
proaches to delivering PrEP services. Numerous barriers
have been described that delay or block AGYW from
accessing clinic-based health services, especially repro-
ductive health and HIV testing and prevention services.
Consequently, reaching AGYW at scale with HIV pre-
vention services requires delivery platforms outside of
clinic-based facilities. Our use of community-based plat-
forms to increase AGYW’s access to PrEP and provide
same-day initiation is novel. If found to be acceptable
and feasible, CBCT platforms can be used to target PrEP
services to other at-risk and key populations.
Recent work has highlighted that positive peer support
[63–65] and cognitive-behavioural problem-solving [46,
66] consistently improve medication adherence among
adults and adolescents. Peer norms play an important
role in shaping behaviours, especially for adolescents
and young people [67, 68], and community-based ap-
proaches that build on peer support may have a strong
influence on young women. Our group-based health
clubs are highly innovative because they will (1) draw on
peer support and cohesion to promote prevention-
effective adherence to PrEP to prevent HIV infection, (2)
provide a forum for adherence support outside the for-
mal clinic environment, (3) create a positive group norm
around the use of PrEP, and (4) provide a space to build
social relationships and bonds with other AGYW who
are using PrEP. If found to be effective, our prevention-
effective adherence support interventions may be tailor
for other at-risk groups and communities. Finally, given
South Africa’s embrace of group-based ART adherence
programmes [69, 70], our adherence support interven-
tion will be well positioned to be integrated into South
Africa’s current adherence support strategies.
Our study has both benefits and limitations of note.
Many PrEP studies involving AGYW have required par-
ticipants to be sexually active and/or “at-risk” [18–20,
71, 72]. By eliminating these inclusion criteria, we may
be able to extend PrEP services and study involvement
to AGYW that provide socially desirable answers to sex-
ual activity and risk behaviour questions. Another bene-
fit will be the provision of regular HIV and STI testing,
and hepatitis B vaccination services. Though similar ser-
vices are provided by local health clinics, participants
may perceive or truly experience diminished barriers
due to the nature and positioning of our community-
based services. Of concern, by randomizing participants
to a specific support modality, we may be overlooking
the specific and/or unique needs and life-styles of indi-
viduals. As such, poor efficacy of an intervention arm
may not be the true result of the modality itself, but due
to the poor matching of a behavioural intervention to in-
dividuals. By conducting in-depth interviews with
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participants, we expect to assess this potential limitation.
Finally, the ability to quickly form health club groups
with a critical mass of participants will be impacted by
the pace of recruitment. To minimize this potential chal-
lenge, study staff will closely monitor recruitment rates
and initially create smaller groups that can be merged
over time to ensure group critical mass. Moreover, given
school, work, and familial responsibilities, scheduling of
health clubs to ensure consistent attendance by a critical
mass of participants may be logistically challenging. To
address this, health clubs will be flexibly scheduled to
maximize participant attendance.
Findings from our study will provide insight into up-
take and prevention-effective use of PrEP to prevent
HIV infection by AGYW in both urban and rural con-
texts. Identifying a prevention-effective adherence inter-
vention suitable for this key population will provide
researchers and clinicians with an additional tool inte-
gral for the rollout of PrEP. The cost-effectiveness ana-
lysis will provide policy makers with the information
they need to make evidence-based decisions on the
structure and components for a PrEP programme. Fi-
nally, the results of our study aim to inform approaches
and guidelines related to PrEP programme implementa-
tion, rollout, and scale-up in South Africa and other
sub-Saharan countries.
Trial status
This trial was retrospectively registered with
ClinicalTrials.gov (NCT03977181) on June 6, 2019. Par-
ticipant recruitment was initiated on October 22, 2018,
with enrolment completion on November 15, 2019. Par-
ticipant follow-up will continue through November
2022. Protocol version 1.5, 22 May 2019.
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